HU

Hutchmed (China) Limited

Biopharmaceutical firm developing targeted therapies for cancer and immune diseases.

HCM | HKEX

Overview

Corporate Details

ISIN(s):
KYG4672N1198 (+1 more)
LEI:
2138006X34YDQ6OBYE79
Country:
Hong Kong
Address:
LEVEL 18, THE METROPOLIS TOWER, KOWLOON

Description

Hutchmed is a commercial-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapeutics and immunotherapies. The company operates a fully integrated platform, advancing a pipeline of novel drug candidates for the treatment of cancer and immunological diseases. Its research and development strategy focuses on creating highly selective and potent therapies engineered to improve drug exposure and reduce off-target toxicities. Hutchmed has multiple internally discovered medicines approved and marketed for various oncology and immunology indications, supported by a global commercialization infrastructure.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-17 08:25
HUTCHMED Initiates Development of ATTC Candidate
English 18.9 KB
2025-12-08 08:35
Expanded NRDL Coverage + CIDL Inclusion in China
English 20.9 KB
2025-11-28 09:40
Total Voting Rights
English 12.6 KB
2025-11-27 08:30
HUTCHMED Highlights Data at ESMO and ASH
English 34.0 KB
2025-11-05 08:25
Enrollment Complete in SAFFRON Global Phase III
English 29.9 KB
2025-11-03 08:30
Updates from R&D Event
English 23.6 KB
2025-10-23 08:00
HUTCHMED Presents Data at AACR NCI EORTC
English 20.4 KB
2025-10-21 10:30
Vesting of awards under Long Term Incentive Plan
English 41.6 KB
2025-10-14 10:30
Appointment of Independent Non-executive Director
English 20.0 KB
2025-10-13 08:05
Data to be Presented at the 2025 ESMO Congress
English 23.1 KB
2025-10-02 08:00
HUTCHMED Highlights Data to be Presented at ESMO
English 32.5 KB
2025-09-30 10:30
Total Voting Rights
English 13.3 KB
2025-09-12 08:00
HUTCHMED to Present R&D Updates on October 31 2025
English 14.2 KB
2025-09-05 08:00
HUTCHMED Highlights Data to be Presented at CSCO
English 37.5 KB
2025-08-26 08:00
Directorate Change
English 17.9 KB

Automate Your Workflow. Get a real-time feed of all Hutchmed (China) Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Hutchmed (China) Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Hutchmed (China) Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.